Alyeska Investment Group
AXSM icon

Alyeska Investment Group’s Axsome Therapeutics AXSM Stock Holding History

Alyeska Investment Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.92M Buy
+20,091
New +$4.36M 0.01% 505
2023
Q3 		– Sell
-125,000
Closed -$8.98M – 503
2023
Q2 		$8.98M Buy
+125,000
New +$9.22M 0.07% 277

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Alyeska Investment Group's AXSM Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 20,091 shares worth $4.92M. The stake represents 0.01% of the portfolio and ranks #505 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in AXSM as recently as Q2 2023.

Alyeska Investment Group first reported a position in AXSM in Q2 2023 and has held it in 2 quarters since. The position peaked at $8.98M in Q2 2023. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Alyeska Investment Group held 20,091 shares of Axsome Therapeutics worth $4.92M as of Q2 2026.
  • Axsome Therapeutics was a new Alyeska Investment Group position in Q2 2026.
  • Axsome Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #505 holding.
  • Alyeska Investment Group first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • Alyeska Investment Group's Axsome Therapeutics position peaked at $8.98M in Q2 2023.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.